The DESTINY-Breast06 trial (NCT04494425), which is currently under investigation, is further exploring the efficacy and safety of T-DXd in the ultra-low expression of HER2 (IHC> 0 but <1+) breast cancer patients. The gene discussed is ERBB2; the disease is breast carcinoma.